IP Library Granted Patent US 11,304,928
Granted Patent B2
US 11,304,928 · App. 16/063,833 · Granted Apr 19, 2022

Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof

Inventors: Atsushi Kano (Toyama, JP); Hiroyuki Inaba (Toyama, JP); Tai Oura (Toyama, JP)
Assignee: FUJIFILM Toyama Chemical Co., Ltd.
A61K31/397A61K9/2054A61K9/28A61K47/12A61K47/26A61K47/32A61K47/38A61P25/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,304,928
App. No.
16/063,833
Granted
Apr 19, 2022
Kind
B2
Abstract

A tablet which comprises (1) 1-(3-(2-(1-benzothiophen-5- yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and (2) ethyl cellulose, said tablet having excellent elution properties and good moldability, remaining stable during prolonged storage, and exhibiting high impact resistance.

Claims (13)

1. A tablet having improved impact strength comprising:

(1) 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof;

(2) 2-5% based on the mass of the tablets ethyl cellulose

(3) 0.5 to 3% based on the mass of the tablets of microcrystalline cellulose;

(4) mannitol; and

(5) from 0.1 to 10% based on the tablet mass of a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone and mixtures thereof; and

the tablet's impact strength is greater than that of a tablet of the same composition except not comprising ethyl cellulose when measured in the falling impact test.

2. The tablet according to claim 1 , further comprising magnesium stearate.

3. The tablet according to claim 1 , wherein the tablet is a film coated tablet.

4. A method for therapy of a disease of the central nerve or the peripheral nerve, comprising administering the tablet according to claim 1 to a subject in need thereof.

5. A method for treating a disease in which neurogenesis induction is effective for therapy, comprising administering the tablet according to claim 1 to a subject in need thereof.

6. A method for enhancing an effect of post-nerve injury rehabilitation, comprising administering the tablet according to claim 1 to a subject in need thereof.

7. The tablet according to claim 1 , wherein the tablet is an uncoated tablet.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Nov 19, 2018
From: FUJIFILM RI PHARMA CO., LTD.; TOYAMA CHEMICAL CO., LTD.
To: FUJIFILM TOYAMA CHEMICAL CO., LTD.
Reel/Frame 047536/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2018
From: KANO, ATSUSHI; INABA, HIROYUKI; OURA, TAI
To: TOYAMA CHEMICAL CO., LTD.
Reel/Frame 046176/0603 →
Priority Claims (1)
JP JP2015-253928 · Dec 25, 2015 · national
Continuity (1)
Related Publication 20180369194A1 · Dec 27, 2018